Efficacy and Safety Phase II Study of SR-T100 to Treat Actinic Keratosis



Status:Completed
Conditions:Dermatology
Therapuetic Areas:Dermatology / Plastic Surgery
Healthy:No
Age Range:18 - Any
Updated:12/7/2018
Start Date:February 2013
End Date:October 2018

Use our guide to learn which trials are right for you!

A Double-blind, Randomized, Vehicle-controlled, Parallel-group, Phase II Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Patients With Actinic Keratosis (AK)

This Phase II study is to evaluate the efficacy of SR-T100 gel with 2.3% of SM in Solanum
undatum plant extract in patient with Actinic Keratosis (AK).


Inclusion Criteria:

1. Male or female; aged ≥ 18 years old.

2. Patient who accepts to enter the study by signing written informed consent.

3. Patient has 4 to 8 clinically diagnosed, discrete, non-hyperkeratotic,
non-hypertrophic AK, located with or without a contiguous 25cm2 areas.

4. Patient allows biopsy to be performed on selected lesion.

5. Patient agrees to apply the study medication on prescribed treatment area with an
occlusive dressing at least 20 hours per day.

6. Patient agrees photographs to be taken on selected lesion and used as part of the
study data package.

7. Patient in good general health condition (performance status ≤ 2 Eastern Cooperative
Oncology Group (ECOG).

8. Sexually active female patient with child-bearing potential must take reliable
contraception method(s) during the participation of the study.

Exclusion Criteria:

1. Patient with recurrent invasive squamous cell carcinoma (SCC).

2. Patient has grossly suspicious or inflamed lymph nodes on physical examination.

3. Patient has evidence of clinically significant or unstable medical conditions.

4. Patient has any skin condition in the treatment area that may be made worse by
treatment.

5. Patient currently uses or had used on the treatment area(s) OTC retinol products,
corticosteroids, cryosurgery, curettage, 5-fluorouracil (5-FU), imiquimod, topical
diclofenac, retinoids, or other topical AK treatments (such as laser abrasion,
dermabrasion, glycolic acids, or chemical peels) 28 days prior to screening visit.

6. Patient had received systemic cancer chemotherapy or immunosuppressant; on the target
evaluation area that psoralen plus UVA therapy, UVB therapy were treated 6 months
prior to screening visit.

7. Patient currently uses or has used prednisone and/or prednisolone (≥ 10 mg or the
equivalent) more than 2 weeks continuously within 12 weeks prior to randomization
visit.

8. Engaging in activities involving excessive or prolonged exposure to sunlight.

9. History of allergy or sensitivity to related compounds or other components of the
investigational product formulation.

10. Woman who is pregnant, lactating or planning to become pregnant during the study.

11. Patient used any investigational drug within 8 weeks prior to the screening visit.
We found this trial at
8
sites
Spokane, Washington 99204
Principal Investigator: William P Werschler, MD
Phone: 509-343-3710
?
mi
from
Spokane, WA
Click here to add this to my saved trials
2095 Langhorne Road
Lynchburg, Virginia 24501
434-847-8400
Principal Investigator: David C. Wilson, MD
?
mi
from
Lynchburg, VA
Click here to add this to my saved trials
1897 Palm Beach Lakes Boulevard
West Palm Beach, Florida 33409
561-689-0606
Principal Investigator: John Goodman, MD
?
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Katy, Texas 77494
Principal Investigator: Suzanne Bruce, MD
Phone: 832-858-3050
?
mi
from
Katy, TX
Click here to add this to my saved trials
Longmont, Colorado 80501
Principal Investigator: Todd Becker, MD
Phone: 303-771-9000
?
mi
from
Longmont, CO
Click here to add this to my saved trials
Pflugerville, Texas 78660
Principal Investigator: Edward L. Lain, MD
Phone: 512-279-2545
?
mi
from
Pflugerville, TX
Click here to add this to my saved trials
Rancho Mirage, California 92270
Principal Investigator: Timothy M. Jochen, MD
Phone: 760-778-7799
?
mi
from
Rancho Mirage, CA
Click here to add this to my saved trials
West Palm Beach, Florida 33406
Principal Investigator: Barry Kuttner, MD
Phone: 561-964-6664
?
mi
from
West Palm Beach, FL
Click here to add this to my saved trials